CST3 and glioblastoma: Notably, CST3 expression was negatively correlated with overall survival in patients with esophageal cancer, glioblastoma, kidney clear cell carcinoma, lower-grade glioma, liver cancer, lung squamous cell carcinoma, stomach cancer, and ocular melanoma (Fig. 6a).